NSEGeneral Updates15h ago · 18 Nov 2026, 05:15 pm
General Updates
Piramal Pharma Limited · PPLPHARMA
✦ AI SummaryM&A
Piramal Pharma Limited has informed the Exchange about exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited, a subsidiary of the Company.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Piramal Pharma Limited has informed the Exchange about exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited
Attachments (1)
📄pdf
Download →
Priyankamehta_18112026171520_SE_Disclosure_Call_Option_Exercise.pdf
View document text
18th November, 2026
BSE Limited National Stock Exchange of India Limited
P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex,
Mumbai- 400 001 Bandra (East), Mumbai – 400 051
BSE scrip code: 543635 NSE symbol: PPLPHARMA
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 as amended (‘SEBI Listing Regulations’) – exercise
of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited
Dear Sir / Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, we wish to inform that the Administrative Committee of the Board of Directors
of Piramal Pharma Limited (‘the Company’), acting under the authority delegated by the Board, has
approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan
Bio Private Limited (‘Yapan’), a subsidiary of the Company, from its existing shareholders (‘the
Proposed Transaction’).
Consequent to the exercise of the call option, the Company is engaged in discussions with the
shareholders of Yapan in relation to matters necessary for consummation of the Proposed
Transaction.
The final terms of the acquisition, including the acquisition consideration and the effective date of
transfer of shares, are yet to be finalized. The Company will make appropriate disclosures including
the details as required under Regulation 30 of the Securities Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 read with Securities Exchange of
Board of India Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30,
2026, upon execution of definitive documentation and completion of the Proposed Transaction.
Yapan is a Contract Development and Manufacturing Organization that specializes in process
development, characterization and Phase I/II GMP manufacturing services for vaccines and
biologics.
Upon completion of the proposed transaction the Company’s shareholding in Yapan is expected to
increase from the existing 74% to 100%, and Yapan will become a wholly owned subsidiary of the
Company.
Kindly take the above on record.
Thank you,
Yours truly,
For Piramal Pharma Limited
Maneesh Sharma
Company Secretary & Compliance Officer
Piramal Pharma Limited
CIN: L24297MH2020PLC338592
Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India
Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com
www.piramalpharma.com